Next-generation outer membrane vesicle vaccines from concept to clinical trials

Only vaccines containing outer membrane vesicles (OMV) have successfully stopped Neisseria meningitidis serogroup B epidemics. The OMV vaccines, however, provide limited coverage and are difficult to produce. This is caused by an obligatory detergent treatment, which removes lipopolysaccharide (LPS), a toxic OMV component. This thesis explored an alternative approach, based on OMV with attenuated lpxL1-LPS and a detergent-free process. The alternative approach is referred to as ‘next-generation OMV’ and provided vaccines with improved immunological and biochemical properties. In addition, quantitative proteomics demonstrated a preferred protein composition. This provided justification for further development towards clinical trials. After optimization of specific process steps, an improved pilot-scale production process was developed. The quality of OMV from this optimized process was stable and within pre-set specifications for nine consecutive batches. Studies in mice and rabbits suggested that next-generation OMV are immunogenic and safe for parenteral use in humans. Therefore these vaccines are now ready for clinical evaluation. Several groups are developing broadly protective OMV vaccines against N. meningitidis serogroup B, but also against other serogroups and other pathogens. OMV therefore have the potential to become a versatile technology platform for prophylactic and therapeutic vaccines. Such a platform requires a reliable production process to generate substantial quantities of high quality product. The process described in this thesis is well-suited for this purpose. The results encourage technology transfer to a commercial partner, with the goal to translate nextgeneration OMV technology into actual vaccines and improve global public health.

Saved in:
Bibliographic Details
Main Author: van de Waterbeemd, B.
Other Authors: Wijffels, Rene
Format: Doctoral thesis biblioteca
Language:English
Subjects:neisseria meningitidis, vaccine development, vaccines, vaccinontwikkeling, vaccins,
Online Access:https://research.wur.nl/en/publications/next-generation-outer-membrane-vesicle-vaccines-from-concept-to-c
Tags: Add Tag
No Tags, Be the first to tag this record!
id dig-wur-nl-wurpubs-438795
record_format koha
spelling dig-wur-nl-wurpubs-4387952024-10-23 van de Waterbeemd, B. Wijffels, Rene Eppink, Michel Doctoral thesis Next-generation outer membrane vesicle vaccines from concept to clinical trials 2013 Only vaccines containing outer membrane vesicles (OMV) have successfully stopped Neisseria meningitidis serogroup B epidemics. The OMV vaccines, however, provide limited coverage and are difficult to produce. This is caused by an obligatory detergent treatment, which removes lipopolysaccharide (LPS), a toxic OMV component. This thesis explored an alternative approach, based on OMV with attenuated lpxL1-LPS and a detergent-free process. The alternative approach is referred to as ‘next-generation OMV’ and provided vaccines with improved immunological and biochemical properties. In addition, quantitative proteomics demonstrated a preferred protein composition. This provided justification for further development towards clinical trials. After optimization of specific process steps, an improved pilot-scale production process was developed. The quality of OMV from this optimized process was stable and within pre-set specifications for nine consecutive batches. Studies in mice and rabbits suggested that next-generation OMV are immunogenic and safe for parenteral use in humans. Therefore these vaccines are now ready for clinical evaluation. Several groups are developing broadly protective OMV vaccines against N. meningitidis serogroup B, but also against other serogroups and other pathogens. OMV therefore have the potential to become a versatile technology platform for prophylactic and therapeutic vaccines. Such a platform requires a reliable production process to generate substantial quantities of high quality product. The process described in this thesis is well-suited for this purpose. The results encourage technology transfer to a commercial partner, with the goal to translate nextgeneration OMV technology into actual vaccines and improve global public health. en application/pdf https://research.wur.nl/en/publications/next-generation-outer-membrane-vesicle-vaccines-from-concept-to-c 10.18174/255898 https://edepot.wur.nl/255898 neisseria meningitidis vaccine development vaccines neisseria meningitidis vaccinontwikkeling vaccins Wageningen University & Research
institution WUR NL
collection DSpace
country Países bajos
countrycode NL
component Bibliográfico
access En linea
databasecode dig-wur-nl
tag biblioteca
region Europa del Oeste
libraryname WUR Library Netherlands
language English
topic neisseria meningitidis
vaccine development
vaccines
neisseria meningitidis
vaccinontwikkeling
vaccins
neisseria meningitidis
vaccine development
vaccines
neisseria meningitidis
vaccinontwikkeling
vaccins
spellingShingle neisseria meningitidis
vaccine development
vaccines
neisseria meningitidis
vaccinontwikkeling
vaccins
neisseria meningitidis
vaccine development
vaccines
neisseria meningitidis
vaccinontwikkeling
vaccins
van de Waterbeemd, B.
Next-generation outer membrane vesicle vaccines from concept to clinical trials
description Only vaccines containing outer membrane vesicles (OMV) have successfully stopped Neisseria meningitidis serogroup B epidemics. The OMV vaccines, however, provide limited coverage and are difficult to produce. This is caused by an obligatory detergent treatment, which removes lipopolysaccharide (LPS), a toxic OMV component. This thesis explored an alternative approach, based on OMV with attenuated lpxL1-LPS and a detergent-free process. The alternative approach is referred to as ‘next-generation OMV’ and provided vaccines with improved immunological and biochemical properties. In addition, quantitative proteomics demonstrated a preferred protein composition. This provided justification for further development towards clinical trials. After optimization of specific process steps, an improved pilot-scale production process was developed. The quality of OMV from this optimized process was stable and within pre-set specifications for nine consecutive batches. Studies in mice and rabbits suggested that next-generation OMV are immunogenic and safe for parenteral use in humans. Therefore these vaccines are now ready for clinical evaluation. Several groups are developing broadly protective OMV vaccines against N. meningitidis serogroup B, but also against other serogroups and other pathogens. OMV therefore have the potential to become a versatile technology platform for prophylactic and therapeutic vaccines. Such a platform requires a reliable production process to generate substantial quantities of high quality product. The process described in this thesis is well-suited for this purpose. The results encourage technology transfer to a commercial partner, with the goal to translate nextgeneration OMV technology into actual vaccines and improve global public health.
author2 Wijffels, Rene
author_facet Wijffels, Rene
van de Waterbeemd, B.
format Doctoral thesis
topic_facet neisseria meningitidis
vaccine development
vaccines
neisseria meningitidis
vaccinontwikkeling
vaccins
author van de Waterbeemd, B.
author_sort van de Waterbeemd, B.
title Next-generation outer membrane vesicle vaccines from concept to clinical trials
title_short Next-generation outer membrane vesicle vaccines from concept to clinical trials
title_full Next-generation outer membrane vesicle vaccines from concept to clinical trials
title_fullStr Next-generation outer membrane vesicle vaccines from concept to clinical trials
title_full_unstemmed Next-generation outer membrane vesicle vaccines from concept to clinical trials
title_sort next-generation outer membrane vesicle vaccines from concept to clinical trials
url https://research.wur.nl/en/publications/next-generation-outer-membrane-vesicle-vaccines-from-concept-to-c
work_keys_str_mv AT vandewaterbeemdb nextgenerationoutermembranevesiclevaccinesfromconcepttoclinicaltrials
_version_ 1816160069151096832